Longevity & Healthspan Interventions
Maturity
1 / 5
Basis, source, vintage
All human data are early-phase and no biomarker of ageing is accepted by the FDA or EMA as a trial endpoint.
Source: Hickson et al., EBioMedicine 47:446–456 (2019), first-in-human senolytic pilot N=9; UNITY UBX0101 Phase 2 (N=183) missed its primary endpoint, 17 Aug 2020; Ying et al., Nature Aging 4:231–246 (2024) on epigenetic clocks as surrogate endpoints (2019–2024)
What it is
Interventions aimed at the biology of ageing itself — senolytics, metabolic and cellular reprogramming approaches.
What it does
It targets the upstream driver of most age-related disease at once, rather than treating each disease separately. If it works even partially, the demographic and fiscal consequences are large.
Common misconception
That the field has demonstrated human results. Animal data is genuinely striking, human trials are early, and this is among the most overclaimed areas in this Compendium.
Steepens
- Longevity and the Healthspan Gap — large · ○ shared candidate constraint (with 1 others)
- The Care Economy — moderate · ○ candidate constraint
- The Silver Economy — moderate · ○ candidate constraint
- Fertility Collapse — marginal · marginal: not counted in the minimum
What would change its gradient
- Validated biomarkers of ageing, which would shorten trials from decades to years
- Regulatory recognition of ageing as an indication
- Nothing on the enthusiasm side — funding is not the constraint here
Shares megatrends with
- Assistive & Care Technology
- Family Formation
- Regenerative Medicine
- Brain-Computer Interfaces
- BioTech & Genomics
- Gene Editing
In the book
Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 14 — How Hype Is Manufactured
Sources
- All human data are early-phase and no biomarker of ageing is accepted by the FDA or EMA as a trial endpoint. Source: Hickson et al., EBioMedicine 47:446–456 (2019), first-in-human senolytic pilot N=9; UNITY UBX0101 Phase 2 (N=183) missed its primary endpoint, 17 Aug 2020; Ying et al., Nature Aging 4:231–246 (2024) on epigenetic clocks as surrogate endpoints (2019–2024).